T. Rowe Price Associates’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.72M	Buy	560,746 +145,383	+35%	+$562K	﹤0.01%	1891
2025 Q4	$1.7M	Buy	415,363 +96,479	+30%	+$478K	﹤0.01%	1825
2025 Q3	$1.56M	Buy	318,884 +37,217	+13%	+$195K	﹤0.01%	1849
2025 Q2	$1.43M	Buy	281,667 +57,433	+26%	+$282K	﹤0.01%	1808
2025 Q1	$1.19M	Buy	224,234 +92,244	+70%	+$672K	﹤0.01%	1869
2024 Q4	$893K	Buy	131,990 +19,552	+17%	+$131K	﹤0.01%	2021
2024 Q3	$741K	Buy	112,438 +24,323	+28%	+$174K	﹤0.01%	2089
2024 Q2	$661K	Buy	88,115 +26,050	+42%	+$227K	﹤0.01%	2070
2024 Q1	$619K	Buy	62,065 +5,501	+10%	+$61.3K	﹤0.01%	2124
2023 Q4	$558K	Buy	56,564 +3,589	+7%	+$25.6K	﹤0.01%	2130
2023 Q3	$406K	Sell	52,975 -23,851	-31%	-$238K	﹤0.01%	2213
2023 Q2	$574K	Buy	76,826 +2,033	+3%	+$14.2K	﹤0.01%	2058
2023 Q1	$499K	Sell	74,793 -1,126	-1%	-$8.93K	﹤0.01%	2107
2022 Q4	$585K	Buy	75,919 +39,713	+110%	+$389K	﹤0.01%	2061
2022 Q3	$386K	Buy	36,206 +13,406	+59%	+$136K	﹤0.01%	2260
2022 Q2	$186K	Sell	22,800 -539,390	-96%	-$3.61M	﹤0.01%	2625
2022 Q1	$4.03M	Sell	562,190 -295,383	-34%	-$3.14M	﹤0.01%	1499
2021 Q4	$14.7M	Buy	857,573 +276,903	+48%	+$5.21M	﹤0.01%	1342
2021 Q3	$13.4M	Sell	580,670 -2,415	-0.4%	-$68.4K	﹤0.01%	1387
2021 Q2	$21.3M	Buy	+583,085	New	+$17.3M	﹤0.01%	1288